The mechanistic interaction, aggregation and neurotoxicity of α-synuclein after interaction with glycyrrhizic acid: Modulation of synucleinopathies

Int J Biol Macromol. 2024 May;267(Pt 2):131423. doi: 10.1016/j.ijbiomac.2024.131423. Epub 2024 Apr 5.

Abstract

This article reveals the binding mechanism between glycyrrhizic acid (GA) and α-synuclein to may provide further information for the modulation of synucleinopathies using bioactive compounds. Therefore, the inhibitory activities of GA against α-synuclein aggregation and induced neurotoxicity were evaluated using different assays. Results showed that α-synuclein-GA binding was mediated by intermolecular hydrogen bonds leading to the formation of a slightly folded complex. Theoretical studies revealed that GA binds to the N-terminal domain of α-synuclein and triggers a compact structure around a major part of the N-terminal and the NAC regions along with fluctuations in the C-terminal domain, which are prerequisites for the inhibition of α-synuclein aggregation. Then, the cellular assays showed that GA as a potential small molecule can inhibit the oligomerization of α-synuclein and relevant neurotoxicity through modulation of neural viability, membrane leakage, and ROS formation in a concentration-dependent manner. As a result, the primary mechanism of GA's anti-aggregation and neuroprotective activities is the reorganized α-synuclein structure and fluctuating C-terminal domain, which promotes long-range transient intramolecular contacts between the N-terminal and the C-terminal domain.

Keywords: Glycyrrhizic acid; Interaction; α-Synuclein.

MeSH terms

  • Cell Survival / drug effects
  • Glycyrrhizic Acid* / chemistry
  • Glycyrrhizic Acid* / pharmacology
  • Humans
  • Hydrogen Bonding
  • Molecular Docking Simulation
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / pharmacology
  • Protein Aggregates* / drug effects
  • Protein Aggregation, Pathological / drug therapy
  • Protein Aggregation, Pathological / metabolism
  • Protein Binding
  • Reactive Oxygen Species / metabolism
  • Synucleinopathies* / metabolism
  • Synucleinopathies* / pathology
  • alpha-Synuclein* / chemistry
  • alpha-Synuclein* / metabolism

Substances

  • alpha-Synuclein
  • Glycyrrhizic Acid
  • Neuroprotective Agents
  • Protein Aggregates
  • Reactive Oxygen Species